Logo image of AND.CA

ANDLAUER HEALTHCARE GROUP IN (AND.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:AND - CA0342231077 - Common Stock

54.97 CAD
+0.01 (+0.02%)
Last: 11/4/2025, 7:00:00 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to AND. AND was compared to 14 industry peers in the Health Care Providers & Services industry. AND has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. AND is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year AND was profitable.
In the past year AND had a positive cash flow from operations.
Each year in the past 5 years AND has been profitable.
In the past 5 years AND always reported a positive cash flow from operatings.
AND.CA Yearly Net Income VS EBIT VS OCF VS FCFAND.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

The Return On Assets of AND (9.81%) is better than 80.00% of its industry peers.
The Return On Equity of AND (15.35%) is better than 86.67% of its industry peers.
Looking at the Return On Invested Capital, with a value of 11.76%, AND belongs to the top of the industry, outperforming 86.67% of the companies in the same industry.
AND had an Average Return On Invested Capital over the past 3 years of 11.97%. This is above the industry average of 7.27%.
Industry RankSector Rank
ROA 9.81%
ROE 15.35%
ROIC 11.76%
ROA(3y)9.88%
ROA(5y)11.71%
ROE(3y)15.44%
ROE(5y)22.37%
ROIC(3y)11.97%
ROIC(5y)12.76%
AND.CA Yearly ROA, ROE, ROICAND.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

The Profit Margin of AND (10.37%) is better than 86.67% of its industry peers.
In the last couple of years the Profit Margin of AND has remained more or less at the same level.
The Operating Margin of AND (13.99%) is better than 86.67% of its industry peers.
In the last couple of years the Operating Margin of AND has remained more or less at the same level.
With a Gross Margin value of 33.85%, AND is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
AND's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 13.99%
PM (TTM) 10.37%
GM 33.85%
OM growth 3Y-4.81%
OM growth 5Y-1.42%
PM growth 3Y-21.44%
PM growth 5Y-0.72%
GM growth 3Y-14.76%
GM growth 5Y-10.42%
AND.CA Yearly Profit, Operating, Gross MarginsAND.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

8

2. Health

2.1 Basic Checks

AND has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
AND has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, AND has more shares outstanding
AND has a worse debt/assets ratio than last year.
AND.CA Yearly Shares OutstandingAND.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AND.CA Yearly Total Debt VS Total AssetsAND.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

AND has an Altman-Z score of 6.13. This indicates that AND is financially healthy and has little risk of bankruptcy at the moment.
AND has a Altman-Z score of 6.13. This is amongst the best in the industry. AND outperforms 93.33% of its industry peers.
The Debt to FCF ratio of AND is 1.80, which is an excellent value as it means it would take AND, only 1.80 years of fcf income to pay off all of its debts.
AND's Debt to FCF ratio of 1.80 is amongst the best of the industry. AND outperforms 100.00% of its industry peers.
AND has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
AND's Debt to Equity ratio of 0.21 is amongst the best of the industry. AND outperforms 93.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 1.8
Altman-Z 6.13
ROIC/WACC1.44
WACC8.16%
AND.CA Yearly LT Debt VS Equity VS FCFAND.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.3 Liquidity

AND has a Current Ratio of 1.35. This is a normal value and indicates that AND is financially healthy and should not expect problems in meeting its short term obligations.
AND has a Current ratio of 1.35. This is amongst the best in the industry. AND outperforms 93.33% of its industry peers.
AND has a Quick Ratio of 1.30. This is a normal value and indicates that AND is financially healthy and should not expect problems in meeting its short term obligations.
AND has a Quick ratio of 1.30. This is amongst the best in the industry. AND outperforms 93.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.3
AND.CA Yearly Current Assets VS Current LiabilitesAND.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.96% over the past year.
AND shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.82% yearly.
AND shows a small growth in Revenue. In the last year, the Revenue has grown by 0.34%.
AND shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.53% yearly.
EPS 1Y (TTM)1.96%
EPS 3Y-10.45%
EPS 5Y14.82%
EPS Q2Q%-10.53%
Revenue 1Y (TTM)0.34%
Revenue growth 3Y13.91%
Revenue growth 5Y17.53%
Sales Q2Q%-3%

3.2 Future

AND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.62% yearly.
Based on estimates for the next years, AND will show a small growth in Revenue. The Revenue will grow by 1.95% on average per year.
EPS Next Y6.54%
EPS Next 2Y10.13%
EPS Next 3Y8.62%
EPS Next 5YN/A
Revenue Next Year0.03%
Revenue Next 2Y1.88%
Revenue Next 3Y1.95%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AND.CA Yearly Revenue VS EstimatesAND.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
AND.CA Yearly EPS VS EstimatesAND.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 35.24, AND can be considered very expensive at the moment.
66.67% of the companies in the same industry are more expensive than AND, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.19. AND is valued slightly more expensive when compared to this.
A Price/Forward Earnings ratio of 28.68 indicates a quite expensive valuation of AND.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AND indicates a somewhat cheap valuation: AND is cheaper than 73.33% of the companies listed in the same industry.
AND is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.88, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 35.24
Fwd PE 28.68
AND.CA Price Earnings VS Forward Price EarningsAND.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AND is valued a bit cheaper than 66.67% of the companies in the same industry.
AND's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 21.69
EV/EBITDA 14.03
AND.CA Per share dataAND.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of AND may justify a higher PE ratio.
PEG (NY)5.39
PEG (5Y)2.38
EPS Next 2Y10.13%
EPS Next 3Y8.62%

3

5. Dividend

5.1 Amount

With a yearly dividend of 0.87%, AND is not a good candidate for dividend investing.
AND's Dividend Yield is a higher than the industry average which is at 1.18.
With a Dividend Yield of 0.87, AND pays less dividend than the S&P500 average, which is at 1.94.
Industry RankSector Rank
Dividend Yield 0.87%

5.2 History

The dividend of AND decreases each year by -34.89%.
AND has been paying a dividend for over 5 years, so it has already some track record.
AND has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-34.89%
Div Incr Years3
Div Non Decr Years3
AND.CA Yearly Dividends per shareAND.CA Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 0.1 0.2 0.3 0.4

5.3 Sustainability

26.73% of the earnings are spent on dividend by AND. This is a low number and sustainable payout ratio.
DP26.73%
EPS Next 2Y10.13%
EPS Next 3Y8.62%
AND.CA Yearly Income VS Free CF VS DividendAND.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
AND.CA Dividend Payout.AND.CA Dividend Payout, showing the Payout Ratio.AND.CA Dividend Payout.PayoutRetained Earnings

ANDLAUER HEALTHCARE GROUP IN

TSX:AND (11/4/2025, 7:00:00 PM)

54.97

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-11 2025-11-11/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners76.5%
Inst Owner ChangeN/A
Ins Owners2.53%
Ins Owner ChangeN/A
Market Cap2.15B
Revenue(TTM)650.58M
Net Income(TTM)67.49M
Analysts50
Price Target56.92 (3.55%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.87%
Yearly Dividend0.42
Dividend Growth(5Y)-34.89%
DP26.73%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.25%
Min EPS beat(2)-19.85%
Max EPS beat(2)-10.65%
EPS beat(4)0
Avg EPS beat(4)-9.2%
Min EPS beat(4)-19.85%
Max EPS beat(4)-0.99%
EPS beat(8)1
Avg EPS beat(8)-8.84%
EPS beat(12)3
Avg EPS beat(12)-6.41%
EPS beat(16)5
Avg EPS beat(16)11.49%
Revenue beat(2)0
Avg Revenue beat(2)-4.56%
Min Revenue beat(2)-7.25%
Max Revenue beat(2)-1.87%
Revenue beat(4)0
Avg Revenue beat(4)-3.59%
Min Revenue beat(4)-7.25%
Max Revenue beat(4)-1.87%
Revenue beat(8)1
Avg Revenue beat(8)-3.17%
Revenue beat(12)4
Avg Revenue beat(12)-1.94%
Revenue beat(16)7
Avg Revenue beat(16)0.32%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.43%
EPS NY rev (1m)-0.79%
EPS NY rev (3m)-6.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.5%
Valuation
Industry RankSector Rank
PE 35.24
Fwd PE 28.68
P/S 3.31
P/FCF 21.69
P/OCF 17.59
P/B 4.89
P/tB 17.04
EV/EBITDA 14.03
EPS(TTM)1.56
EY2.84%
EPS(NY)1.92
Fwd EY3.49%
FCF(TTM)2.53
FCFY4.61%
OCF(TTM)3.13
OCFY5.69%
SpS16.62
BVpS11.23
TBVpS3.23
PEG (NY)5.39
PEG (5Y)2.38
Graham Number19.86
Profitability
Industry RankSector Rank
ROA 9.81%
ROE 15.35%
ROCE 16.09%
ROIC 11.76%
ROICexc 13.13%
ROICexgc 34.45%
OM 13.99%
PM (TTM) 10.37%
GM 33.85%
FCFM 15.25%
ROA(3y)9.88%
ROA(5y)11.71%
ROE(3y)15.44%
ROE(5y)22.37%
ROIC(3y)11.97%
ROIC(5y)12.76%
ROICexc(3y)12.48%
ROICexc(5y)13.78%
ROICexgc(3y)30.54%
ROICexgc(5y)29.2%
ROCE(3y)16.39%
ROCE(5y)17.47%
ROICexgc growth 3Y-1.36%
ROICexgc growth 5Y-1.14%
ROICexc growth 3Y4.48%
ROICexc growth 5Y-13.43%
OM growth 3Y-4.81%
OM growth 5Y-1.42%
PM growth 3Y-21.44%
PM growth 5Y-0.72%
GM growth 3Y-14.76%
GM growth 5Y-10.42%
F-Score5
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 1.8
Debt/EBITDA 0.56
Cap/Depr 32.65%
Cap/Sales 3.56%
Interest Coverage 250
Cash Conversion 75.6%
Profit Quality 147.02%
Current Ratio 1.35
Quick Ratio 1.3
Altman-Z 6.13
F-Score5
WACC8.16%
ROIC/WACC1.44
Cap/Depr(3y)36.55%
Cap/Depr(5y)30.34%
Cap/Sales(3y)3.8%
Cap/Sales(5y)3.06%
Profit Quality(3y)141.22%
Profit Quality(5y)125.45%
High Growth Momentum
Growth
EPS 1Y (TTM)1.96%
EPS 3Y-10.45%
EPS 5Y14.82%
EPS Q2Q%-10.53%
EPS Next Y6.54%
EPS Next 2Y10.13%
EPS Next 3Y8.62%
EPS Next 5YN/A
Revenue 1Y (TTM)0.34%
Revenue growth 3Y13.91%
Revenue growth 5Y17.53%
Sales Q2Q%-3%
Revenue Next Year0.03%
Revenue Next 2Y1.88%
Revenue Next 3Y1.95%
Revenue Next 5YN/A
EBIT growth 1Y-1.92%
EBIT growth 3Y8.43%
EBIT growth 5Y15.86%
EBIT Next Year74.49%
EBIT Next 3Y25.3%
EBIT Next 5YN/A
FCF growth 1Y6.06%
FCF growth 3Y11.81%
FCF growth 5Y13.66%
OCF growth 1Y-1.91%
OCF growth 3Y13.94%
OCF growth 5Y15.32%

ANDLAUER HEALTHCARE GROUP IN / AND.CA FAQ

What is the ChartMill fundamental rating of ANDLAUER HEALTHCARE GROUP IN (AND.CA) stock?

ChartMill assigns a fundamental rating of 6 / 10 to AND.CA.


What is the valuation status of ANDLAUER HEALTHCARE GROUP IN (AND.CA) stock?

ChartMill assigns a valuation rating of 3 / 10 to ANDLAUER HEALTHCARE GROUP IN (AND.CA). This can be considered as Overvalued.


How profitable is ANDLAUER HEALTHCARE GROUP IN (AND.CA) stock?

ANDLAUER HEALTHCARE GROUP IN (AND.CA) has a profitability rating of 7 / 10.


What is the earnings growth outlook for ANDLAUER HEALTHCARE GROUP IN?

The Earnings per Share (EPS) of ANDLAUER HEALTHCARE GROUP IN (AND.CA) is expected to grow by 6.54% in the next year.


Is the dividend of ANDLAUER HEALTHCARE GROUP IN sustainable?

The dividend rating of ANDLAUER HEALTHCARE GROUP IN (AND.CA) is 3 / 10 and the dividend payout ratio is 26.73%.